284 related articles for article (PubMed ID: 26372358)
1. Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.
Dorman SN; Baranova K; Knoll JH; Urquhart BL; Mariani G; Carcangiu ML; Rogan PK
Mol Oncol; 2016 Jan; 10(1):85-100. PubMed ID: 26372358
[TBL] [Abstract][Full Text] [Related]
2. Predicting Outcomes of Hormone and Chemotherapy in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Study by Biochemically-inspired Machine Learning.
Mucaki EJ; Baranova K; Pham HQ; Rezaeian I; Angelov D; Ngom A; Rueda L; Rogan PK
F1000Res; 2016; 5():2124. PubMed ID: 28620450
[TBL] [Abstract][Full Text] [Related]
3. Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.
Jørgensen CL; Ejlertsen B; Bjerre KD; Balslev E; Nielsen DL; Nielsen KV
BMC Cancer; 2013 Nov; 13():541. PubMed ID: 24215511
[TBL] [Abstract][Full Text] [Related]
4. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
5. Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine.
Liang K; Lu Y; Li X; Zeng X; Glazer RI; Mills GB; Fan Z
Mol Pharmacol; 2006 Sep; 70(3):1045-52. PubMed ID: 16782806
[TBL] [Abstract][Full Text] [Related]
6. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
Kwon WS; Rha SY; Choi YH; Lee JO; Park KH; Jung JJ; Kim TS; Jeung HC; Chung HC
Pharmacogenet Genomics; 2006 Jun; 16(6):429-38. PubMed ID: 16708051
[TBL] [Abstract][Full Text] [Related]
7. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.
Rha SY; Jeung HC; Choi YH; Yang WI; Yoo JH; Kim BS; Roh JK; Chung HC
Oncologist; 2007 Jun; 12(6):622-30. PubMed ID: 17602053
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and paclitaxel as salvage therapy in metastatic breast cancer.
Murad AM; Guimarães RC; Aragão BC; Scalabrini'Neto AO; Rodrigues VH; Garcia R
Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):25-7. PubMed ID: 11252885
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
Demiray M; Kurt E; Evrensel T; Kanat O; Arslan M; Saraydaroglu O; Ercan I; Gonullu G; Gokgoz S; Topal U; Tolunay S; Tasdelen I; Manavoglu O
Cancer Invest; 2005; 23(5):386-91. PubMed ID: 16193637
[TBL] [Abstract][Full Text] [Related]
10. Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial.
Lee KS; Ro J; Lee ES; Kang HS; Kim SW; Nam BH; Kwon Y; Kim EA; Shin KH
Invest New Drugs; 2010 Feb; 28(1):83-90. PubMed ID: 19229476
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine for the treatment of metastatic breast cancer.
Jones J; Takeda A; Tan SC; Cooper K; Loveman E; Clegg A
Health Technol Assess; 2009 Sep; 13 Suppl 2():1-7. PubMed ID: 19804683
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ
Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
Georgoulias VA
Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):18-24. PubMed ID: 11252884
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer.
Smyth EN; Shen W; Bowman L; Peterson P; John W; Melemed A; Liepa AM
Health Qual Life Outcomes; 2016 Mar; 14():52. PubMed ID: 27016084
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.
Albain KS; Nag SM; Calderillo-Ruiz G; Jordaan JP; Llombart AC; Pluzanska A; Rolski J; Melemed AS; Reyes-Vidal JM; Sekhon JS; Simms L; O'Shaughnessy J
J Clin Oncol; 2008 Aug; 26(24):3950-7. PubMed ID: 18711184
[TBL] [Abstract][Full Text] [Related]
16. Role of Gemcitabine in Breast Cancer Management: An Update.
Wirk B; Perez E
Semin Oncol; 2006 Feb; 33(Suppl 2):S6-14. PubMed ID: 16472712
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells.
Zupi G; Scarsella M; D'Angelo C; Biroccio A; Paoletti G; Lopez M; Leonetti C
Cancer Biol Ther; 2005 Aug; 4(8):866-71. PubMed ID: 16210917
[TBL] [Abstract][Full Text] [Related]
18. Influence of genetic markers on survival in non-small cell lung cancer.
Rosell R; Taron M; Camps C; López-Vivanco G
Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
Delfino C; Caccia G; Riva Gonzáles L; Mickiewicz E; Rodger J; Balbiani L; Flores Morales D; Zori Comba A; Brosio C
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):22-5. PubMed ID: 14768401
[TBL] [Abstract][Full Text] [Related]
20. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
Zhang J; Lin Y; Sun XJ; Wang BY; Wang ZH; Luo JF; Wang LP; Zhang S; Cao J; Tao ZH; Wu J; Shao ZM; Yang WT; Hu XC
Ann Oncol; 2018 Aug; 29(8):1741-1747. PubMed ID: 29905759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
